Ghali Shravan Kumar

Mr. Ghali Shravan Kumar

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2022 in Phytomedicine Plus
Verified
Journal Article
Open access
GKGhali Shravan Kumar
Ghali Shravan Kumar
TRTowseef Amin Rafeeqi
Towseef Amin Rafeeqi
GHGulam Mohammed Husain
Gulam Mohammed Husain
GJGhazala Javed
Ghazala Javed
MWMohammed Abdul Waheed
Mohammed Abdul Waheed
ACAlokananda Chakraborty
Alokananda Chakraborty

23 April 2022 in Research Journal of Pharmacy and Technology
Verified
Journal Article
Closed access
LKLahari Kuna
Lahari Kuna
GKGhali Shravan Kumar
Ghali Shravan Kumar
TRTowseef Amin Rafeeqi
Towseef Amin Rafeeqi
GHGulam Mohammed Husain
Gulam Mohammed Husain
MWMohammed Abdul Waheed
Mohammed Abdul Waheed
ACAlokananda Chakraborty
Alokananda Chakraborty

30 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MAMohd Anas
Mohd Anas
GHGulam Mohammed Husain
Gulam Mohammed Husain
TATasleem Ahmed
Tasleem Ahmed
UVUzma Viquar
Uzma Viquar
MNMohammed Abdul Rasheed Naikodi
Mohammed Abdul Rasheed Naikodi
MZMohammad Zakir
Mohammad Zakir
Background: Diabetes mellitus (DM) is one of the most common non-communicable diseases impacting millions worldwide. There is immense need for cost effective and safer alternative therapies for diabetes for developing countries like India where majority of population rely on traditional medicine for their healthcare needs.Objectives: Present study was conducted to evaluate the antidiabetic effects of a compound Unani formulation (CUF) in animal models.Materials and methods: Test formulation (CUF) was prepared as per traditional method. Oral glucose tolerance test (OGTT) was performed in euglycemic normal rats to assess peripheral utilization of glucose. Nicotinamide Streptozotocin-induced Non-Insulin Dependent Diabetes Mellitus (NIDDM) model was used for evaluating anti-diabetic effect in Wistar rats. CUF (600 and 1200 mg/kg) and positive control glibenclamide (10 mg/kg) was administered orally for 28-days and blood glucose level was analyzed on 14th and 28th day. Anti-oxidant potential of CUF was also conducted using DDPH, ABTS and FRAP scavenging assay.Results: CUF markedly reduced glucose levels in OGTT in normal rats for up to 60 minutes at both dose levels. In NIDDM model, CUF demonstrated a significant reduction in fasting blood glucose level on 14th and 28th days of treatment. The formulation has shown promising antioxidant results. The results are in agreement with the ethnopharmacological use of the formulation. Conclusion: Findings of present study advocate antidiabetic potential of CUF and it may be a cost-effective and safe anti-diabetic formulation for developing world.